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doi:10.1016/j.ejvs.2008.11.041Abstract Objectives: To compare expanded polytetrafluoroethylene (ePTFE) prosthesis and
collagen-impregnated knitted polyester (Dacron) for above-knee (AK) femoro-popliteal bypass
grafts.
Design: A prospective multicentre randomised clinical trial.
Patients and Methods: Between 1992 and 1996, 228 AK femoro-popliteal bypass grafts were
randomly allocated to either an ePTFE (nZ 114) or a Dacron (nZ 114) vascular graft (6 mm
in diameter). Patients were eligible for inclusion if presenting with disabling claudication, rest
pain or tissue loss.
Follow-up was performed and included clinical examination and duplex ultrasonography at
all scheduled intervals. All patients were treated with warfarin.
The main end-point of this study was primary patency of the bypass graft at 2, 5 and 10 years
after implantation. Secondaryend-pointsweremortality, primary assistedpatency andsecondary
patency. Cumulativepatency rateswere calculatedwith life-table analysis andwith log-rank test.
Results: After 5 years, the primary, primary assisted and secondary patency rates were 36%
(confidence interval (CI): 26e46%), 46% (CI: 36e56%) and 51% (CI: 41e61%) for ePTFE and 52%
(CI: 42e62%) (pZ 0.04), 66% (CI: 56e76%) (pZ 0.01) and 70% (CI: 60e80%) (pZ 0.01) for Dacron,
respectively. After ten years these rates were respectively 28% (CI:18-38%), 31% (CI:19-43%) and
35% (CI: 23-47%) for ePTFE and 28% (CI: 18-38%), 49% (CI: 37-61%) and 49% (CI: 37-61%) for Dacron.
Conclusion: During prolonged follow-up (10 years), Dacron femoro-popliteal bypass grafts have
superior patency compared to those of ePTFE grafts. Dacron is the graft material of choice if
the saphenous vein is not available.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.4872510; fax: þ31 53 4872526.
is-mst.nl (R.J. van Det).
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Femoro-popliteal bypass grafting has been shown to be an
effective treatment for arterial occlusive disease in
patients with severe claudication or critical ischaemia.
Autogenous venous conduits are associated with improved
patency for both above- and below-knee femoro-popliteal
bypass.1,2 Prosthetic graft material is still a frequently used
alternative to venous conduits due to the absence of
a good-quality long saphenous vein in many patients.3 The
choice of prosthetic graft material, such as expanded pol-
ytetrafluoroethylene (ePTFE) or Dacron, for femoro-popli-
teal bypass grafts has been controversial over the past
decade.4 Seven randomised clinical trials have been con-
ducted to compare the outcome of ePTFE or Dacron for
femoro-popliteal bypass.5e13 However, interpretation of
these studies is difficult due to a number of problems in the
design of the investigations, including short follow-up time,
the inclusion of both supra- and infrageniculate bypasses
and the inclusion of different graft diameters. Conse-
quently, no firm conclusions have been reached on whether
ePTFE or Dacron is preferable.14,15
The present study was conducted to answer the ques-
tion whether an ePTFE or a Dacron prosthesis should be
used for suprageniculate femoro-popliteal allograft bypass
grafting.Table 1 Patient characteristics
Parameter ePTFE n (%)
N 114
Gender limbs M/F 74/40
Age (yrs) mean, (range) 66 (43e89)
Co-morbidity (%)
DM 37 (32.5)
Hypertension 45 (39.5)
Cerebrovascular disease 19 (16.7)
Cardiac disease 41 (36.0)
Smoking
Never 21 (18.4)
<10 per day 26 (22.8)
>10 per day 35 (30.7)
Quit 32 (28.1)
Ischaemia category (Rutherford classification)
1 3 (2.6)
2 44 (38.6)
3 42 (36.8)
4 10 (8.8)
5 15 (13.2)
No. patent crural vesselsc
0 1 (0.9)
1 31 (27.2)
2 38 (33.3)
3 44 (38.6)
a For categorical variables Pearson’s chi-square test were used.
b For continuous variables Student’s t-test was used.
c A vessel was still ‘patent’, even if a significant stenosis was presePatients and Methods
Recruitment for this multicentre randomised trial was
carried out from July 1992 until August 1996. The follow-up
was extended until June 2007. The protocol followed the
rules of the Helsinki declaration and the Consolidated
Standards of Reporting Trials (CONSORT) reporting stan-
dards have been used. Patient consent was obtained in all
cases. Patients were eligible for inclusion if they presented
with symptoms of disabling claudication, rest pain or tissue
loss and suprageniculate femoro-popliteal bypass was
feasible. Exclusion criteria were previous ipsilateral fem-
oro-popliteal procedures, contraindication to long-term
anticoagulant therapy, life expectancy less than 1 year and
current treatment with chemotherapy or radiotherapy.
The preoperative assessment followed The Society for
Vascular Surgery/International Society for Cardiovascular
Surgery (SVSeISCVS) risk score,16 including detailed
evaluation of patient history, cardiovascular risk factors,
physical examinations, ankleebrachial index (ABI) and
intra-arterial digital subtraction angiography (DSA).
Randomisation was stratified for each centre using
sealed envelopes. The physician treating the patient could
not be blinded to the treatment allocation.
The operation was performed with general or regional
anaesthesia. All patients received antibiotic prophylaxisDacron n (%) df Test
value
p-value
114
73/41 1 c2Z 0.02 0.89a
67 (39e92) 226 tZ0.60 0.99b
30 (26.3) 1 c2Z 1.04 0.31a
38 (33.3) 1 c2Z 0.93 0.34a
8 (7.0) 1 c2Z 5.08 0.02a
33 (28.9) 1 c2Z 1.28 0.26a
3 c2Z 5.94 0.12a
16 (14.0)
18 (15.8)
31 (27.2)
49 (43.0)
4 c2Z 0.82 0.94a
5 (4.4)
40 (35.1)
42 (36.8)
10 (8.8)
17 (14.9)
3 c2Z 2.04 0.56a
0 (0.0)
27 (24.1)
45 (40.2)
40 (35.7)
nt.
Above-knee Fem-pop Bypass Dacron or ePTFE 459consisting of Cefazoline according to local guidelines.
Before arterial clamping, 5000 units of heparin were given
intravenously. Anastomoses were performed end-to-side,
with 6/0 Prolene (Johnson & Johnson; Ethicon, St Stevens-
Woluwe, Belgium), proximal to the common femoral artery
and distal to the above-knee popliteal artery. Post-
operatively, all patients were given Warfarin.
The grafts used were either 6-mm expanded, stretched,
thin-walled PTFE (Goretex, W.L. Gore & Ass., Flagstaff,
AZ, USA) or a 6-mm collagen-impregnated Dacron (Hema-
shield, Meadox, Oakland, NJ, USA) (Boston Scientific,
Maquet). The patients were scheduled for follow-up after 3
and 6 weeks, 3, 6, 9, 12, 18 and 24 months, and yearly up to
10 years. Review consisted of clinical consultation,Assessed for elig
(not available
Analyzed (n=114)
Excluded from analysis (n=0)
Lost to follow-up (n=3)
- incomplete follow-up
Discontinued intervention (n=74)
-     Death: 73
-    Graft Removal: 1
Allocated to ePTFE
(n=114)
Received allocated intervention
(n=114)
Did not receive allocated intervention
(n=0)
Allocat
Analys
Follow-
Enrollment
Figure 1 CONSORT-flowcharta physical examination, ABI and a duplex scan. After
surgery and at 1 year a DSA was performed.
The main end-points of this study were primary patency
rates of the bypass 2, 5 and 10 years after implantation.
Secondary end-points were mortality, primary assisted
patency and secondary patency.
In accordance with the SVSeISCVS16 guidelines, primary
patency was defined as uninterrupted patency without any
manipulation of the graft. Primary assisted patency was
defined as uninterrupted graft patency, but maintained by
prophylactic intervention like angioplasty, patch angio-
plasty or small graft interpositions. Secondary patency was
defined as restored patency after occlusion with or without
revision of the graft.ibility
)  
Excluded (n=not available)
Not meeting inclusion criteria
(n=not available)
Refused to participate
(n=not available)
Other reasons
(n=not available)
Lost to follow-up (n=1)
- incomplete follow-up
Discontinued intervention (n=67)
-     Death: 65 
-    Graft Removal: 2 
Allocated to Dacron
(n=114)
Received allocated intervention
(n=114)
Did not receive allocated intervention
(n=0)
Analyzed (n=114)
Excluded from analysis (n=0)
ion
is
Up
of participants in the study.
Table 2 Cumulative patency rates (%)
Patency Follow-up time
(years)
ePTFE
(%)
SE 95% CI
(%)
Dacron
(%)
95% CI
(%)
SE df c2 p-value
Primarya 2 64 0.05 54e74 70 62e78 0.04 1 0.78
5 36 0.05 26e46 52 42e62 0.05 1 4.39 0.04
10 28 0.05 18e38 28 18e38 0.05 1 2.39 0.12
Primary assisted a 2 72 0.04 72e80 77 69e84 0.04 1 0.93
5 46 0.05 36e56 66 56e76 0.05 1 6.64 0.01
10 31 0.06 19e43 49 37e61 0.06 1 7.45 0.01
Secondarya 2 78 0.04 70e86 84 76e92 0.04 1 1.04
5 51 0.05 41e61 70 60e80 0.05 1 6.50 0.01
10 35 0.06 23e47 49 37e61 0.06 1 6.10 0.01
a Based on life-tables, corrected for censored patients at the respective end of each interval.
460 R.J. van Det et al.Statistics
Patients could be included in the study twice for operations
performed on different legs. Analyses of the end-points
were performed per limb.
When testing the hypothesis there was a 20% difference
in primary patency between both grafts at the end of 5-year
follow-up, it was calculated by a two-sided power analysis
that the study needed at least 110 grafts in each group to
obtain sufficient statistical power (aZ 0.05 and
powerZ 85%).
Cumulative patency rates were calculated with life-table
analysis by the KaplaneMeier method and compared with
the log-rank test. Differences between the two groups for
categorical data were analysed by means of Pearson’s chi-
square test and for continuous variables by Student’s t-test.Follow-up (months)
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Figure 2 KaplaneMeier analysis of primary patency rates for
PTFE and Dacron.A p-value of <0.05 was considered significant. All anal-
yses were done on an intention-to-treat basis and per-
formed with SPSS, V.15.01.
Results
A total of 228 limbs (219 patients) were randomly
allocated for reconstruction with either Dacron
(nZ 114) or ePTFE (nZ 114) between July 1992 and
August 1996 in five hospitals in the Netherlands (Medisch
Spectrum Twente, Enschede, nZ 60/60, Twenteborg
Hospital, Almelo, nZ 18/19; Slingeland Hospital, Doe-
tinchem, nZ 17/15 General Hospital Midden-Twente,
Hengelo nZ 18/20, Koningin Beatrix Hospital, Winter-
swijk nZ 1/0).
The group consisted of 147 (64%) male and 81 (36%)
female limbs. Preoperative risk factors were diabetesC
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Figure 3 KaplaneMeier analysis of primary assisted patency
rates for PTFE and Dacron.
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Figure 4 KaplaneMeier analysis of secondary patency rates
for PTFE and Dacron.
Above-knee Fem-pop Bypass Dacron or ePTFE 461(nZ 67; 29.4%), hypertension (nZ 83; 36.4%), cardiac
disease (nZ 74; 32.5%), cerebrovascular disease (nZ 27;
11.8%) and smoking (nZ 110; 48.2%). Baseline character-
istics were equally divided between both groups, except for
cerebrovascular disease, which was significantly lower in
the Dacron group (Table 1).Table 3 Patency results from existing RCT on femoro-popliteal
Patients
(no)
Above-knee
n (%)
Follow-up time
(years)
Primar
PTFE (
Erasmi, 1996 103 103 (100) 1.5 e
Green, 2000 240 240 (100) 5 43
Robinson, 1999 108 75 (69) 1 72
2 52
3 52
Devine, 2004a 209 179 (86) 1 66
3 49
5 41
Post, 2001 194 141 (73) 3 70
Robinson, 2003 129 76 (59) 0.5 71
1 56
2 47
Jensen, 2007 427 427 (100) 2 57
Van Det, 2008 228 228 (100) 2 64
5 36
10 28
a Com, compared heparin-bonded Dacron with PTFE.Patients included in the trial were distributed between
chronic limb ischaemia (CLI) grade I e 77% (category 1, 2
and 3, respectively, 3%, 37% and 37%), CLI grade II e 9% and
CLI grade III e 14%, based on the Rutherford classification.
One hundred and twenty-two of the bypass grafts were
performed under general anaesthesia (62 in the ePTFE group
and 60 in the Dacron group). The remaining bypasses were
performed with regional anaesthesia. All patients received
heparin intra-operatively, and, in 224 limbs, the anasto-
moses of the bypass grafts were performed with prolene.
After 10 years only four (1.8%) patients were lost to
follow-up. There was no in-hospital mortality, but two
patients died in the first 30 days postoperatively, one in
each group. The postoperative infection grade III was 0.9%.
After 2, 5 and 10 years, 28 (12.8%), 70 (32.0%) and 133
(60.7%), respectively, of the initial 219 patients had died; of
whom, 22 (78.6%), 41 (58.6%) and 67 (50.4%) patients,
respectively, had a primary patent bypass.
Patient allocation and follow-up is outlined in Fig. 1.
Occlusion of the bypass graft within 30 days post-
operatively was seen in three limbs; of these, one (0.9%)
was in the ePTFE group and two (1.8%) were in the Dacron
group. Overall primary patency rates were 66.2%, 49.6% and
40.4% at 2, 5 and 10 years postoperatively.
The 2-year primary, primary assisted and secondary
patency rates were 64%, 72% and 78% for ePTFE and 70%
(log-rank test, pZ 0.38), 77% (log-rank test, pZ 0.33) and
84% (log-rank test, pZ 0.31) for Dacron, respectively. The
5-year primary, primary assisted and secondary patency
rates were 36%, 46% and 51% for ePTFE and 52% (log-rank
test, pZ 0.04), 66% (log-rank test, pZ 0.01) and 70% (log-
rank test, pZ 0.01) for Dacron, respectively. The 10-year
primary, primary assisted and secondary patency rates
were 28%, 31% and 35% for ePTFE and 28% (log-rank test,
pZ 0.12), 49% (log-rank test, pZ 0.01) and 49% (log-rankbypass comparing PTFE versus Dacron
y patency p-value Secondary patency p-value
%) Dacron (%) PTFE (%) Dacron (%)
e 79.6 87.1 NS
45 NS 68 68 NS
70 NS 74 78 NS
56 NS 54 70 NS
47 NS 54 53 NS
76 NS 63 73 NS
59 NS 48 55 NS
50 NS 36 47 NS
62 NS 75 81 NS
50 NS 77 66 NS
36 NS 60 49 NS
36 PZ 0.00 48 46 NS
70 PZ 0.02 65 76 PZ 0.04
70 NS 78 84 NS
52 PZ 0.04 51 70 PZ 0.01
28 NS 35 49 PZ 0.01
462 R.J. van Det et al.test, pZ 0.01) for Dacron, respectively (Table 2 and Figs.
2e4).
After 10 years, seven above-knee amputations had been
performed: three (2.6%) in the ePTFE group and four (3.5%)
in the Dacron group. Below-knee amputations had been
performed 4 (3.5%) times in the group with ePTFE and 5
(4.4%) times in the Dacron group.Discussion
This study showed that Dacron provided significantly
improved long-term graft patency compared to ePTFE when
used for suprageniculate femoro-popliteal bypass.
In the last decade, it has become clear that the patency
rates for venous grafts are superior to that of ePTFE for
femoro-popliteal bypass.1,4,8,17e19
In the last three decades, nearly exclusively based on
personal preference and experience, opinion leaders have
suggested that if autologous graft material was not avail-
able, PTFE was the preferred prosthetic material for fem-
oro-distal bypass surgery.19e28 However, until the present
study, there has been no conclusive evidence on which to
base the choice of prosthetic graft material for a supra-
geniculate femoro-popliteal bypass. Retrospective studies
comparing PTFE with knitted Dacron at 5 years had
produced varied results.23,29 Several randomised controlled
trials have been published comparing PTFE and Dacron,
again with varied results (Table 3).6,7,9e12
One of the first published trials comparing PTFE and
knitted Dacron polyester suprageniculate grafts rando-
mised 244 patients. After 3 years, there was no statistically
significant difference in primary or secondary patency rates
between the two grafts.6 In a further trial, the 5-year
primary patency rates of PTFE and Dacron were similar;
however, different graft diameters were used in this trial,
making interpretation of results difficult.9
Post et al. compared PTFE with Dacron prosthesis in 203
patients. They included both supra- and infrageniculate
femoro-popliteal bypasses, but primary patency rates of
both groups were analysed separately. Patency rates for
suprageniculate grafts were similar at 3 years.10
The trial of Robinson and co-workers also included both
supra- and infrageniculate femoro-popliteal bypasses. They
found no significant difference in primary and secondary
patency rates at 1, 2 and 3 years. The patency rates
reported in that study were considerably lower than found
in the current trial.7 The same Australian group compared
fluoropolymer-coated Dacron to PTFE in 129 patients
receiving both above- and below-knee reconstructions and
used grafts of different sizes. A significant difference was
reported in primary patency after 2 years in favour of PTFE
(47%) over Dacron (36%), whereas the difference in
secondary patency was not significant.11
Devine et al. reported that heparin-bonded Dacron grafts
had improved patency compared to PTFE at the 3-year
follow-up (pZ 0.04). Again, this study included both supra-
and infrageniculate bypasses. When they analysed the group
of the above-knee bypasses separately, the 3-year primary
patency results were 46% for PTFE and 61% for Dacron, which
was significantly different (pZ 0.04). The overall primarypatency rates for the above-knee bypasses in that study
were 71%, 54% and 45% at 1, 3 and 5 years, respectively.
Their 5-year result resembles our overall patency of 40% at 5
years.8,12 It is possible that this difference in patency ach-
ieved between heparin-bonded Dacron and PTFE may be due
to the influence of heparin bonding.
In the most recent randomised controlled trial, Jensen
et al. found better primary and secondary graft patency
rates for Dacron as compared to PTFE. The primary and
secondary patency rates were 70% and 76% for Dacron and
57% (pZ 0.02) and 65% (pZ 0.04) for PTFE at 2 years,
respectively.13
Evidence from the present study has shown that for
a suprageniculate femoro-popliteal bypass, Dacron has
significant superior primary, primary assisted and secondary
patency rates at 5 years of follow-up. After 10 years, the
primary patency rates approach each other; however, the
primary assisted and secondary patency rates still signifi-
cantly favour the use of Dacron prosthesis.
Based on these results, we propose that Dacron should
be preferentially used for prosthetic femoro-popliteal
above-knee reconstructions. This graft choice is also sup-
ported by the fact that a Dacron graft is less expensive than
a PTFE prosthesis.
Developments in graft technology continue and varia-
tions of ePTFE and Dacron grafts with different coatings
have been introduced into the market. These new grafts
have currently not been shown to be superior to older grafts
in well-conducted randomised trials.
The results from our study would justify the preferential
use of Dacron in patients with intermittent claudication or
CLI selected to undergo femoro-popliteal bypass, where
a suitable saphenous vein is absent and a distal above-knee
anastomosis is possible.
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